Document Detail


Role of angiotensin II in the evolution of diastolic heart failure.
MedLine Citation:
PMID:  16330897     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
More than half of all persons with heart failure (HF) have diastolic HF. The prevalence of diastolic HF increases from 46% in persons younger than 45 years to 59% in those 85 years and older. The annual mortality rate associated with diastolic HF is >10%. Diagnosis is based on signs and symptoms of HF, elevated plasma B-type natriuretic peptide, preserved left ventricular systolic function, and evidence of diastolic dysfunction by Doppler examination on two-dimensional echocardiography. Approximately 80% of patients with diastolic HF have increased left ventricular mass and a history of hypertension. Neurohormonal activation is a key aspect of this condition. Studies suggest that activation of the renin-angiotensin-aldosterone system, specifically direct cardiac effects of angiotensin II and aldosterone, contributes to the pathogenesis and progression of diastolic dysfunction. Hence, there is a rationale for use of agents that antagonize the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists, in patients with heart failure.
Authors:
Kavitha M Chinnaiyan; Daniel Alexander; Peter A McCullough
Related Documents :
17478167 - The president and the pheochromocytoma.
3738407 - Circannual rhythms of systolic and diastolic blood pressure in relation to plasma aldos...
3050197 - Periodic fluctuation of blood pressure and its management in a patient with pheochromoc...
18314347 - Primary aldosteronism: cardiovascular, renal and metabolic implications.
17016397 - Mechanical ventilation in acute respiratory distress syndrome.
11198017 - An evaluation of hospital special-ventilation-room pressures.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  7     ISSN:  1524-6175     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-06     Completed Date:  2007-04-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  740-7     Citation Subset:  IM    
Affiliation:
Division of Cardiology and Nutrition, William Beaumont Hospital, Royal Oak, MI 48073, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aldosterone Antagonists / pharmacology,  therapeutic use
Angiotensin II / physiology*
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use
Blood Pressure / physiology
Heart Failure / drug therapy,  etiology*,  mortality
Humans
Hypertension / complications
Hypertrophy, Left Ventricular / etiology
Prognosis
Receptors, Angiotensin / antagonists & inhibitors
Renal Insufficiency / complications
Renin-Angiotensin System / drug effects,  physiology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Receptors, Angiotensin; 11128-99-7/Angiotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Circadian blood pressure and heart rate changes in patients in a persistent vegetative state after t...
Next Document:  Alpha1-adrenergic blockers: current usage considerations.